

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Rationale and design for studying organisation of care for intra-arterial thrombectomy in the Netherlands: a simulation modelling study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032754
Article Type:	Protocol
Date Submitted by the Author:	03-Jul-2019
Complete List of Authors:	Lahr, Maarten ; Health Technology Assessment, Department of Epidemiology, Health Technology Assessment, Department of Epidemiology Maas, Willemijn; University of Groningen, University Medical Centre Groningen, Neurology, Epidemiology van der Zee, Durk-Jouke; Rijksuniversiteit Groningen Faculteit Economie en Bedrijfskunde, Operations Uyttenboogaart, Maarten; University of Groningen, University Medical Centre Groningen, Neurology Buskens, Erik; University of Groningen, University Medical Center Groningen, Epidemiology; University of Groningen, Faculty of Economics and Business, Department of Operations
Keywords:	Stroke < NEUROLOGY, STROKE MEDICINE, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 **Rationale and design for studying organisation of care for intra-arterial thrombectomy**
4 **in the Netherlands: a simulation modelling study**
5
6
7

8 Maarten M.H. Lahr¹, Ph.D.; Willemijn J. Maas^{1,2}, M.Sc; Durk-Jouke van der Zee³, Ph.D;
9 Maarten Uyttenboogaart^{2,4}, M.D., Ph.D.; Erik Buskens^{1,3} M.D., Ph.D, for the CONTRAST
10 investigators.
11

12
13
14 ¹ *Health Technology Assessment, Department of Epidemiology, University of Groningen,*
15 *University Medical Centre Groningen, Groningen, The Netherlands*

16
17 ² *Department of Neurology, University of Groningen, University Medical Centre Groningen,*
18 *Groningen, The Netherlands*

19
20 ³ *Department of Operations, Faculty of Economics & Business, University of Groningen,*
21 *Groningen, The Netherlands*

22
23 ⁴ *Department of Radiology, University of Groningen, University Medical Centre Groningen,*
24 *Groningen, The Netherlands*
25

26
27 **Co-authors addresses:**

28 Willemijn Maas w.j.maas@umcg.nl

29 Durk-Jouke van der Zee d.j.van.der.zee@rug.nl

30 Maarten Uyttenboogaart m.uyttenboogaart@umcg.nl

31 Gert-Jan Luijckx g.j.luickx@umcg.nl

32 Erik Buskens e.buskens@umcg.nl
33
34

35
36 **Key words:** stroke, intra-arterial thrombectomy, intravenous thrombolysis, simulation
37 modelling, organisational model, probability.

38
39 **Word count all sections:** 3951

40 **Word count main text:** 2875

41 **Number of tables:** 0

42 **Number of figures:** 2

43 **Supplementary tables:** 1

44 **Supplementary figures:** 1
45
46

47 **Corresponding Author:**

48 Maarten M.H. Lahr

49 University Medical Centre Groningen, Department of Epidemiology

50 P.O. Box 30001. 9700 RB Groningen, The Netherlands

51 Telephone: + 31 50 361 43 86

52 E-mail: m.m.h.lahr@umcg.nl
53
54
55
56
57
58
59
60

Abstract

Introduction – The introduction of intra-arterial thrombectomy (IAT) challenges acute stroke care organisations to provide fast access to acute stroke therapies. Parameters of pathway performance include distances to primary and comprehensive stroke centres, time to treatment and availability of ambulance services. Further expansion of IAT centres may increase treatment rates, yet, could affect efficient use of resources and quality of care due to lower treatment volume. The aim was to study the organisation of care and patient logistics of IAT for ischaemic stroke patients in the Netherlands.

Methods and analyses – Using a simulation modelling approach, performance of sixteen primary and comprehensive stroke centres offering IAT in the Netherlands will be quantified. Patient data concerning both pre- and intrahospital pathway logistics will be collected and used as input for model validation. A previously validated simulation model for intravenous thrombolysis (IVT) patients will be expanded with data of the MR CLEAN Registry and trials performed in the CONTRAST consortium to represent patient logistics, time delays and outcomes in IAT patients. Simulation experiments aim to assess effectiveness and efficiency of alternative network topologies, i.e. IAT with or without IVT at the nearest primary stroke centre versus centralised care at comprehensive stroke centre (CSC). Primary outcomes are IAT treatment rates and patient disability according to the modified Rankin Scale. Secondary outcomes include onset-to-treatment time and resource use. Mann-Whitney U and Fisher's exact tests will be used to estimate differences for continuous and categorical variables. Model and parameter uncertainty will be tested using sensitivity analyses.

Ethics and dissemination – This will be the first study to examine the organisation of acute stroke care for IAT delivery on a national scale using discrete event simulation. There are no ethics or safety concerns regarding the dissemination of information, which includes publication in peer-reviewed journals and (inter)national conference presentations.

Strengths and limitations of the study

- The proposed simulation modelling study collects patient level data from all interventions centers in the Netherlands that provide IAT for acute ischaemic stroke patients.
- Information from prehospital stroke services including emergency medical services are included in the model.
- Information on costs associated with pathway set-up and innovations foreseen in acute stroke treatment are included.
- Model results are estimations which have to be tested in clinical practice.
- Input parameters for model building contain estimations of time delays and diagnostic procedures that may have changed over time.

For peer review only

INTRODUCTION

For acute ischaemic stroke patients, reperfusion therapies comprise intravenous thrombolysis (IVT) administered up to 4.5 hours after onset, and intra-arterial thrombectomy (IAT) up to 6 hours and in selected patients even up to 24 hours.¹⁻⁷ Functional recovery following treatment is strongly determined by the time interval between symptom onset and reperfusion. For every 9-minute delay along the care pathway, 1 in every 100 patients treated with IAT has a worse disability outcome (higher modified Rankin Scale score by 1 or more levels).⁸ As such, timely arrival at the hospital and minimising the overall onset-to-treatment time is of critical importance. Following symptom onset patients are typically transported to the nearest hospital capable of administering IVT, which can be either a Primary Stroke Centre (PSC) or a Comprehensive Stroke Centre (CSC). In parallel with administering the bolus for IVT additional neuroimaging is performed in order to detect large vessel occlusion (LVO). In case of a LVO patients may become eligible for IAT after which transfer to a CSC is arranged, if patients are initially admitted to a PSC.

The transfer of patients to a CSC following IVT diagnostic work-up and/or treatment at a PSC is called the drip-and-ship (DS) approach. In addition to the DS approach patients may be transported directly to the CSC bypassing the PSC, which is called the Mothership (MS) approach. Currently there are no formal policies supporting the latter, as it necessitates accurate prehospital triage objectifying LVO with sufficient accuracy. Timely patient arrival and treatment with reperfusion therapies depends on a number of factors such as the geographical distribution and distances between PSCs and CSCs in relation to the location of the patient. Arrangements made by local emergency medical services concerning referral patterns of suspected stroke victims, and the quality and set-up of road networks also play a role, as does potential traffic congestion.

In the Netherlands sixteen medical centres that participated in the MR CLEAN trial are currently reimbursed for IAT. However, these hospitals are unevenly distributed leaving certain regions potentially underserved while in some areas there is a surplus of IAT centres. Insight into factors determining the potential optimal and most efficient way to organise acute stroke care is currently lacking but urgently needed to support clinicians and decision-makers. A key question is: what would be the optimal distribution of CSCs within a region, taking into account the effects of additional travel distances, available clinical expertise, treatment volumes and capacity of hospitals? Are there regions under- or overserved with CSCs and what would be the potential consequences of adding/removing CSCs within specific regions?

In this study, we aim to quantify pathway logistics, i.e. stroke onset and time delays associated with pre-hospital and intra-hospital care services among patients treated with IAT with or without IVT. From this baseline assessment a simulation model will be built that describes all activities and treatments performed along the acute stroke pathway. A generic model will be developed based on the set-up of IAT delivery in the region of Northern Netherlands, and extended using results of the MR CLEAN registry⁹ and data of 4 randomised clinical trials (RCTs) performed in the 'Collaboration for new treatments in acute stroke (CONTRAST)' consortium (www.contrast-consortium.nl). Simulation experiments will be performed to assess effectiveness and efficiency of alternative network topologies, i.e. primary and comprehensive stroke services (DS approach) versus a service delivery based on comprehensive and centralised care (MS approach). Model parameters will be extended by assigning unit costs to activities allowing for economic analyses.

Aims and hypotheses

Primary aim: to develop a simulation model for IAT in the Netherlands and to extend the model to reflect regional differences.

Secondary aims: to estimate the effectiveness of alternative network topologies on IVT and/or IAT treatment rates, geographical access to CSCs, time to treatment, treatment volumes and patient disability as measured by the modified Rankin Scale (Mrs). Also, potential areas for pathway improvements in regional stroke care systems will be identified.

Tertiary aims: to extend the model with costs estimations of procedures and activities performed along the acute stroke pathway allowing for elaborate economic evaluation. Also, the assessment and potential implementation of new technologies such as the mobile stroke unit is foreseen through modelling.

METHODS

Study design

This study uses discrete event simulation modelling in which care pathways can be represented ‘in silico’ by quantifying pathway performance.¹⁰⁻¹² In case of acute stroke treatment, information on time delays sustained by patients and diagnostic steps performed up to treatment with IVT and IAT are collected. Previous research has demonstrated that simulation models for representing the acute stroke pathway can be truthfully developed in different settings.¹³⁻¹⁷ Typically, simulation modelling involves a number of consecutive steps including model building, validation and experimentation. Model building starts with the conceptual representation of care pathways in building block such as incidents, time delays, queues, resources and ultimately outcome. Next the model needs to be populated through collection of empirical data reflecting actual pathway performance, for which a combination of real-world datasets are used. For hospital items we will rely on case report forms (CRFs) collected in the RCTs in the CONTRAST consortium involving sixteen hospitals in the Netherlands that provide IAT. In addition, collaboration with regional ambulance services will be set up in order to collect prehospital items such as time of 911 call, time spent on scene, transportation time to the hospital and general referral patterns. Real-world data collected in each step of the pathway will be analysed to distinguish statistical distributions using the statistical software package ExpertFit.¹⁸ Based on the statistical distributions identified hypothetical patients passing through the model will be assigned a certain time delay, and diagnostic accuracy for each step along the pathway. Model outcomes include the proportion of patients treated with IAT, time to treatment and functional outcome after 90 days. These results will then be validated comparing them to observed time delays and outcomes observed in clinical practice. Following model validation, experiments will be performed in which scenarios of alternative set-ups of the organisational models will be evaluated. Descriptions of the acute stroke pathway in both the DS and MS organisational models in Northern Netherlands are presented in Figures 1 and 2.

Figure 1. Description of the drip-and-ship model.





Figure 2. Description of the Mothership model.



Study population

For this study we will use data from acute stroke patients that received IAT with or without IVT. A baseline model will be developed using a subset of patient information collected in the ongoing cohort study MR CLEAN Registry. Following the initial model patients treated in other regions in the Netherlands will be included. In later stages of model development alternative treatment modalities may become apparent such as treating patient with IAT up to 24 hours or including patients that receive prehospital treatment in a mobile stroke unit. In these cases the parameters underlying the model will be changed accordingly.

Public and patient involvement

Patients and public were involved in the conception of the topics to be addressed in the CONTRAST consortium. Study results will be disseminated through newsletters, poster presentations, and publications in newspapers, lay-men journals, and publication in peer-reviewed journals.

Data to be collected

An overview of all data items collected for the simulation model is presented in a table as supplementary material (Table S1. Overview of data collection).

Hospital data

Within CONTRAST 4 RCTs are performed that serve as input for the proposed simulation modelling studies: MR ASAP (NL60258.078.17), MR CLEAN LATE (NL58246.078.17), MR CLEAN MED (ISRCTN76741621), MR CLEAN NO IV (ISRCTN80619088). Each intervention centre uses a standardised, customised and web-based electronic CRF to document all steps in the care process. All data will be entered locally in web-based database (OpenClinica). A copy of the CRF documents used in the clinical trials can be found online (www.contrast-consortium.nl). All studies aim to collect a large set of items containing, among others, a description of the workflow including time of symptom onset or last seen well, time of arrival of the first hospital and whether the patient was transferred from another hospital. Within the hospital, time to computed tomography (CT) scan and advanced imaging (computed tomography angiography/ magnetic resonance angiography/digital subtraction angiography/perfusion imaging) are collected according to local procedures. Also start of IVT (bolus infusion), patient arrival in the angiosuite, groin puncture, device attempts, recanalisation and sheath withdrawal/end of procedure are collected. In addition anesthetic team presence and management procedures are recorded.

Prehospital data

For the collection of prehospital data collaboration with regional ambulance services is being set-up. Items will include time delays, diagnostics and geographic information on referral patterns. Time delays include the time of 911 call, arrival at the location of the patient, departure at the location of the patient and arrival at the hospital. Diagnostic items include mode of referral (general practitioner, 911 or other), initial working diagnosis set by 911 dispatch and ambulance personnel and the level of urgent transportation (i.e. blue lights or

1
2
3 other). Geographical information includes the postal codes of the location of the patient,
4 departure location of the ambulance vehicle and location of the PSC and/or CSC.
5

6 *Baseline data*

7
8 Prior to the CONTRAST study, all hospitals contributed to the MR CLEAN Registry, an
9 online and ongoing database to monitor implementation and safety of IAT in the
10 Netherlands.⁹ For CONTRAST the variables are similar to those collected in the MR CLEAN
11 Registry. In addition, prehospital information available at regional ambulance services will be
12 collected.
13

14 The baseline discrete event simulation model will be developed using data from 296
15 patients that received IAT at the University Medical Centre Groningen between July 2014 and
16 November 2017. For these patients intrahospital time delays and diagnostic steps were already
17 collected as part of the ongoing MR CLEAN Registry and subsequently used for model
18 development and validation. In addition, prehospital items as described above were collected
19 in collaboration with regional ambulance services.
20
21
22

23 **Outcome measures**

24 Outcomes will be estimated by the simulation model using parameter distributions as
25 observed in clinical practice using real-world data.
26
27

28 *Primary outcomes* include IAT treatment rates and patient disability according to the
29 modified Rankin Scale (Mrs).
30

31 *Secondary outcomes* include process times such as symptom onset to hospital arrival, door to
32 needle and groin puncture, arrival angiosuite, recanalization, onset-to-treatment time of IVT
33 and/or IAT and interhospital transportation times for those patients that were transferred to a
34 CSC after initial diagnosis and/or treatment with IVT at a PSC.
35

36 *Tertiary outcomes* include treatment volume, direct costs, indirect costs and societal costs.
37
38
39

40 **Data management and ethics**

41 In order to link patient data collected after study enrollment in the hospital to corresponding
42 data collected by ambulance services, identifiable information from patients will be used
43 under a strict protocol compliant with the Dutch Personal Data Protection Act. This protocol
44 meets the criteria for a waiver of consent from the University Medical Centre Groningen
45 Institutional Review Board. Prior to the exchange of information, a data transfer and
46 processing agreement was agreed upon and signed by each provider of regional ambulance
47 services.
48
49
50

51 **Study sites**

52 Sixteen hospitals providing IAT will participate. In addition, regional ambulance services in
53 the catchment area of intervention centres will be asked to participate. The overview of
54 intervention centres, their catchment area and regional ambulance services active in the region
55 are provided as supplementary material (Figure S1. Overview of IAT centres and ambulance
56 services).
57
58
59
60

Statistical analyses

Descriptive statistics will be used to characterise the population and regional differences. Mann-Whitney U and Fisher's exact tests are used to estimate the differences for continuous and categorical variables. Model and parameter uncertainty will be tested using sensitivity analyses.

Approach to missing data

Multiple imputation techniques will be used to handle missing data. The impact of missing data will be analysed by performing sensitivity analyses. Once missing data or errors are identified, all corrections made will be documented.

Model validation

Internal validation will be performed by comparing model performance with observed performance of the stroke system to ascertain whether the model represented the real system accurately. External validation of the baseline model will be performed by using the pathway performance of other PSCs and CSCs participating in the CONTRAST consortium. As such, the model developed for one region will be extended to other parts of the Netherlands by changing the distributions underlying the simulation model. This means that the model is re-populated by real-world data originating from different regions, including both intrahospital and prehospital data. As we will adopt one uniform method for data collected in both the pre- and intrahospital pathway, similar procedures for model building, validation and experimentation can be followed.

Study organisation

The CONTRAST consortium is a nationwide collaboration of clinical and translational scientists from all academic and large clinical centres who want to act together to improve the treatment of acute stroke in the Netherlands. Four large acute stroke trials to test novel treatment strategies will be performed including: prehospital augmentation of collateral blood flow and blood pressure reduction (MR ASAP), antithrombotics to prevent microvascular occlusion after IAT (MR CLEAN MED), immediate IAT without preceding thrombolysis (MR CLEAN NO IV) and IAT in the 6 to 24 hour time window (MR CLEAN LATE). Discrete event simulation modelling is applied with data from these trials to optimise acute stroke care delivery.

DISCUSSION

This simulation modelling study will evaluate the set-up of acute stroke services for patients receiving IAT in a specific geographical setting, i.e., the Netherlands. However, the model foreseen may also serve as a planning and evaluation tool for other regions and countries. Already from an early phase onwards the potential consequences of the clinical trials performed in CONTRAST on the organisation of acute stroke care will be assessed. Benefits of innovations foreseen in prehospital as well as hospital based diagnosis and treatment will be estimated on a regional and national scale. Likewise, the optimal organisation ensuing from these re-organising care processes may be identified and taken into account given

1
2
3 available resources and capacity. Experiments from simulation models will help to elucidate
4 factors determining optimal stroke pathway set-up and identify potential targets for further
5 optimisation of pathway performance. Simulation modelling also allows for making exact
6 estimations on effects on patients health and costs when adding or removing IAT centres in
7 specific regions, thereby supporting clinicians and policy makers in decision making.¹⁵
8
9

10 Our simulation modelling approach has several strengths. First, the prospective design
11 and uniform methods for data collection both in the pre- and intrahospital phase will ensure a
12 high quality of data capturing. The use of real-world data will support the external validation
13 of results obtained and is a unique feature of the proposed modelling study. Also in terms of
14 efficiency simulation modelling is an attractive option, as it utilizes already collected
15 information in clinical trials and by ambulance services. Second, the model will have a
16 comprehensive scope, contrary to current improvement approaches characterised by mono-
17 dimensional interventions.¹⁹⁻²¹ Proposed solutions following such an approach are per
18 definition finite, and cannot not solve implementation problems such as how many CSCs
19 would a region need or where they should ideally be located. Data used for model input will
20 be collected in various regions of the Netherlands reflecting differences in access to PSCs and
21 CSCs, road networks and potential traffic congestion. Third, the model builds on a previously
22 developed simulation model for IVT treatment in Northern Netherlands.¹⁰ As such we have
23 demonstrated that model building and validation is feasible. Finally, the model can be
24 extended to include unit costs for elaborate economic analyses. The comprehensive character
25 of the modelling approach also allows considering potential interaction effects between
26 variables, and has a quadruple dimensional approach in terms of measuring outcomes, as it
27 can capture effects on clinical outcomes, time to treatment, referral patterns and costs of
28 processes associated with IVT and IAT delivery.
29
30
31

32 Serving as a precursor for clinical validation, results obtained from modelling studies
33 should always be interpreted with care as these results do not represent actual patients.
34 However, from an economics and business approach each treatment can be represented as the
35 sum of time delays and diagnostics performed along the care pathway, and as such can be
36 quantified and in turn represented 'in silico' by computer models. One of the main questions
37 is whether there is benefit in bypassing the nearest PSC to transport the patient directly to a
38 CSC. At the moment there is no consensus which prehospital scale to use in order to quantify
39 stroke severity, and no agreed upon triage instrument exists to guide transfer of patients to
40 specific hospitals. Typically, in case of a positive trial results in CONTRAST this will have a
41 direct impact on the organisational model for IAT delivery, either by suggesting to bypass
42 PSCs (MR CLEAN NO IV), by extending the time window for reperfusion therapies (MR
43 CLEAN LATE) or to change prehospital stroke management (MR ASAP). As a consequence
44 alternative set-up of services is foreseen, in which accurate estimations on effectiveness, time
45 to treatment and cost-effectiveness are required to support decision-making.
46
47
48
49

50 CONCLUSION

51 The proposed modelling study will investigate current organisational models for IAT delivery
52 in the Netherlands. Based on input from real-world clinical studies performed in the
53 CONTRAST consortium insight into current treatment delays and workflow performance of
54 IAT centres will be obtained. Next, simulation modelling studies will support design of
55 optimal distribution of IAT centres, in order to improve patient outcomes and increase the
56 proportion of patients eligible for IAT.
57
58
59
60

Acknowledgements We acknowledge the support of the Netherlands Cardiovascular Research Initiative which is supported by the Dutch Heart Foundation (CVON2015-01: CONTRAST), the support of the Brain Foundation Netherlands (HA2015.01.06), and the support of Health~Holland, Top Sector Life Sciences & Health (LSHM17016) and of Medtronic.

Contributors ML, WM, DJZ, MU and EB designed the study with MU and EB as principal investigators. ML, MU and EB applied for, received and organised study funding. ML drafted the manuscript, WM, DJZ, MU and EB critically revised the manuscript for intellectual content and approved the final version of the manuscript for publication.

Funding The CONTRAST consortium is supported by Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation, by the Brain Foundation Netherlands and powered by Health~Holland, Top Sector Life Sciences and receives unrestricted funding from Medtronic.

Competing interest statement The authors declare that there is no conflict of interest.

References

- 1 . Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med* 1995;333:1581-7.
- 2 Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med* 2015;372:11-20.
- 3 Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med* 2015;372:1009-18.
- 4 Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med* 2015;372:1019-30.
- 5 Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med* 2015;372:2296-306.
- 6 Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med* 2015;372:2285-95.
- 7 Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. *N Engl J Med* 2018;378:11-21.
- 8 Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. *JAMA* 2016;316:1279-88.
- 9 Jansen IGH, Mulder MJHL, Goldhoorn RB, et al. Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). *BMJ* 2018;360:k949.

1
2
3 10 Lahr MM, van der Zee DJ, Vroomen PC, et al. Thrombolysis in acute ischemic stroke: a simulation
4 study to improve pre- and in-hospital delays in community hospitals. *PLoS One* 2013;8:e79049.
5

6 11 Ramwadhoebe S, Van Merode GG, Boere-Boonekamp MM, et al. Implementation by simulation;
7 strategies for ultrasound screening for hip dysplasia in the Netherlands. *BMC Health Serv Res*
8 2010;10:75.
9

10 12 Heeg BM, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia.
11 *Pharmacoeconomics* 2008;26:633-48 doi:2682 [pii].
12

13 13 Holodinsky JK, Williamson TS, Demchuk AM, et al. Modeling Stroke Patient Transport for All
14 Patients With Suspected Large-Vessel Occlusion. *JAMA Neurol* 2018;75:1477-86.
15

16 14 Phan TG, Beare R, Chen J, et al. Googling Service Boundaries for Endovascular Clot Retrieval
17 Hub Hospitals in a Metropolitan Setting: Proof-of-Concept Study. *Stroke* 2017;48:1353-61.
18

19 15 Lahr MM, van der Zee DJ, Luijckx GJ, et al. Centralising and optimising decentralised stroke care
20 systems: a simulation study on short-term costs and effects. *BMC Med Res Methodol* 2017;17:5,016-
21 0275-3.
22

23 16 Monks T, Pitt M, Stein K, et al. Maximizing the Population Benefit From Thrombolysis in Acute
24 Ischemic Stroke: A Modeling Study of In-Hospital Delays. *Stroke* 2012;43(10):2706-11.
25

26 17 Churilov L, Fridriksdottir A, Keshtkaran M, et al. Decision support in pre-hospital stroke care
27 operations: a case of simulation to improve eligibility of acute stroke patients for thrombolysis
28 treatment. *Computer & Operations Research* 2013; 40: 2208–218.
29

30 18 Law AM. ExpertFit Version 8 User's Guide. Tuscon, Arizona: Averill M. Law & Associates 2011.
31

32 19 Jeon SB, Ryoo SM, Lee DH, et al. Multidisciplinary Approach to Decrease In-Hospital Delay for
33 Stroke Thrombolysis. *J Stroke* 2017;19:196-204.
34

35 20 Psychogios MN, Behme D, Schregel K, et al. One-Stop Management of Acute Stroke Patients:
36 Minimizing Door-to-Reperfusion Times. *Stroke* 2017;48:3152-5.
37

38 21 Schregel K, Behme D, Tsogkas I, et al. Effects of Workflow Optimization in Endovascularly
39 Treated Stroke Patients - A Pre-Post Effectiveness Study. *PLoS One* 2016;11:e0169192.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary files

Table S1. Overview of data collection [Table S1.docx] – supplementary material for “Rationale and design of a simulation modelling approach for intra-arterial thrombectomy in the Netherlands” by Lahr M.M. et al.

Table 1. Overview of data collection.

Item	Description	Source
<u>Prehospital items</u>		
Symptom onset	Exact time of stroke onset, last seen well or symptoms noticed	CRF
Mode of referral	Initial call for help directed at either the GP, 911 emergency services or via self-transport	Ambulance database
Time first 911 call	Moment of first 911 call as documented at the control centre of the regional ambulance service	Ambulance database
Time second 911 call†	Moment of second 911 call as documented at the control centre of the regional ambulance service	Ambulance database
Time departure ambulance patient	Moment of ambulance departure in the direction of the patient	Ambulance database
Time departure ambulance hospital	Moment of ambulance departure in the direction of the PSC for transfer to the CSC	Ambulance database
Time ambulance arrival patient	Moment of ambulance arrival at the location of the patient	Ambulance database
Time ambulance arrival first hospital	Moment of ambulance arrival at the first hospital	Ambulance database
Time ambulance arrival second hospital†	Moment of ambulance arrival at the second hospital	Ambulance database
Time ambulance arrival PSC†	Moment of ambulance arrival at the PSC to transfer a patient to the CSC	Ambulance database
Procedures at location patient	All procedures performance by ambulance personnel at the location of the patient	Ambulance database
Postal code patient	Exact geographic location of the patient	Ambulance database
Postal code hospital	Exact geographical location of the destination hospital	Ambulance database
<u>Intrahospital items</u>		
Time of arrival ER first hospital	Moment of patient entry into the hospital electronic system	CRF
Time of arrival ER intervention hospital	Moment of patient entry into the hospital electronic system	CRF
Time of CT scan first hospital	Moment of CT scan performance in the first hospital	CRF
Time of CT scan second hospital	Moment of CT scan performance in the second hospital	CRF
Time of CTA scan first hospital	Moment of CTA scan performance in the first hospital	CRF
Time of CTA scan second hospital	Moment of CTA scan performance in the second hospital	CRF

Time of IV alteplase bolus (if given)	Moment of intravenous thrombolysis	CRF
Time of angiosuite arrival	Moment of patient arrival at the angiosuite	CRF
Time groin puncture	Moment of groin puncture	CRF
Time device attempt	Moment of device attempt	CRF
Time recanalisation	Time of recanalisation	CRF
Time of end procedure	Moment of sheath withdrawal/end of procedure	CRF

CRF indicates case report form; PSC, primary stroke centre; CSC, comprehensive stroke centre; CT, computed tomography; CTA, computed tomography angiogram.

†In case of intravenous thrombolysis at the primary stroke centre followed by intra-arterial thrombectomy at the comprehensive stroke centre (drip-and-ship approach).

Figure S1. Overview of IAT centres and ambulance services [Supplementary figure S1.tiff] - supplementary material for “Rationale and design of a simulation modelling approach for intra-arterial thrombectomy in the Netherlands” by Lahr M.M. et al.



BMJ Open

Rationale and design for studying organisation of care for intra-arterial thrombectomy in the Netherlands: a simulation modelling study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032754.R1
Article Type:	Protocol
Date Submitted by the Author:	31-Oct-2019
Complete List of Authors:	Lahr, Maarten ; Health Technology Assessment, Department of Epidemiology, Health Technology Assessment, Department of Epidemiology Maas, Willemijn; University of Groningen, University Medical Centre Groningen, Neurology, Epidemiology van der Zee, Durk-Jouke; Rijksuniversiteit Groningen Faculteit Economie en Bedrijfskunde, Operations Uyttenboogaart, Maarten; University of Groningen, University Medical Centre Groningen, Neurology Buskens, Erik; University of Groningen, University Medical Center Groningen, Epidemiology; University of Groningen, Faculty of Economics and Business, Department of Operations
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Epidemiology, Health services research
Keywords:	Stroke < NEUROLOGY, STROKE MEDICINE, EPIDEMIOLOGY, Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 1 **Rationale and design for studying organisation of care for intra-arterial thrombectomy**
4 2 **in the Netherlands: a simulation modelling study**
5
6 3

7
8 4 Maarten M.H. Lahr¹, Ph.D.; Willemijn J. Maas^{1,2}, M.Sc; Durk-Jouke van der Zee³, Ph.D;
9 5 Maarten Uyttenboogaart^{2,4}, M.D., Ph.D.; Erik Buskens^{1,3} M.D., Ph.D, for the CONTRAST
10 6 investigators.
11
12 7

13
14 8 ¹ *Health Technology Assessment, Department of Epidemiology, University of Groningen,*
15 9 *University Medical Centre Groningen, Groningen, The Netherlands*

16
17 10 ² *Department of Neurology, University of Groningen, University Medical Centre Groningen,*
18 11 *Groningen, The Netherlands*

19
20 12 ³ *Department of Operations, Faculty of Economics & Business, University of Groningen,*
21 13 *Groningen, The Netherlands*

22
23 14 ⁴ *Department of Radiology, University of Groningen, University Medical Centre Groningen,*
24 15 *Groningen, The Netherlands*
25
26 16

27 17 **Co-authors addresses:**

28 18 Willemijn Maas w.j.maas@umcg.nl

29 19 Durk-Jouke van der Zee d.j.van.der.zee@rug.nl

30 20 Maarten Uyttenboogaart m.uyttenboogaart@umcg.nl

31 21 Erik Buskens e.buskens@umcg.nl
32 22

33
34 23 **Key words:** stroke, intra-arterial thrombectomy, intravenous thrombolysis, simulation
35 24 modelling, organisational model, probability.
36

37 25 **Word count all sections:** 3951

38 26 **Word count main text:** 2875

39 27 **Number of tables:** 0

40 28 **Number of figures:** 2

41 29 **Supplementary tables:** 1

42 30 **Supplementary figures:** 1
43 31
44
45

46 32 **Corresponding Author:**

47 33 Maarten M.H. Lahr

48 34 University Medical Centre Groningen, Department of Epidemiology

49 35 P.O. Box 30001. 9700 RB Groningen, The Netherlands

50 36 Telephone: + 31 50 361 43 86

51 37 E-mail: m.m.h.lahr@umcg.nl
52 38
53 39
54
55
56 40
57
58 41
59
60 42

Abstract

Introduction – The introduction of intra-arterial thrombectomy (IAT) challenges acute stroke care organisations to provide fast access to acute stroke therapies. Parameters of pathway performance include distances to primary and comprehensive stroke centres, time to treatment and availability of ambulance services. Further expansion of IAT centres may increase treatment rates, yet, could affect efficient use of resources and quality of care due to lower treatment volume. The aim was to study the organisation of care and patient logistics of IAT for ischaemic stroke patients in the Netherlands.

Methods and analyses – Using a simulation modelling approach, performance of sixteen primary and comprehensive stroke centres offering IAT in the Netherlands will be quantified. Patient data concerning both pre- and intrahospital pathway logistics will be collected and used as input for model validation. A previously validated simulation model for intravenous thrombolysis (IVT) patients will be expanded with data of the MR CLEAN Registry and trials performed in the CONTRAST consortium to represent patient logistics, time delays and outcomes in IAT patients. Simulation experiments aim to assess effectiveness and efficiency of alternative network topologies, i.e. IAT with or without IVT at the nearest primary stroke centre versus centralised care at comprehensive stroke centre (CSC). Primary outcomes are IAT treatment rates and clinical outcome according to the modified Rankin Scale. Secondary outcomes include onset-to-treatment time and resource use. Mann-Whitney U and Fisher's exact tests will be used to estimate differences for continuous and categorical variables. Model and parameter uncertainty will be tested using sensitivity analyses.

Ethics and dissemination – This will be the first study to examine the organisation of acute stroke care for IAT delivery on a national scale using discrete event simulation. There are no ethics or safety concerns regarding the dissemination of information, which includes publication in peer-reviewed journals and (inter)national conference presentations.

Strengths and limitations of the study

- The proposed simulation modelling study collects patient level data from all interventions centers in the Netherlands that provide IAT for acute ischaemic stroke patients.
- Information from prehospital stroke services including emergency medical services are included in the model.
- Information on costs associated with pathway set-up and innovations foreseen in acute stroke treatment are included.
- Model results are estimations which have to be tested in clinical practice.
- Input parameters for model building contain estimations of time delays and diagnostic procedures that may have changed over time.

For peer review only

1 INTRODUCTION

2 For acute ischaemic stroke patients, reperfusion therapies comprise intravenous thrombolysis
3 (IVT) administered up to 4.5 hours after onset, and intra-arterial thrombectomy (IAT) up to 6
4 hours and in selected patients even up to 24 hours.¹⁻⁷ Functional recovery following treatment
5 is strongly determined by the time interval between symptom onset and reperfusion. For every
6 9-minute delay along the care pathway, 1 in every 100 patients treated with IAT has a worse
7 disability outcome (higher modified Rankin Scale score by 1 or more levels).⁸ As such, timely
8 arrival at the hospital and minimising the overall onset-to-treatment time is of critical
9 importance. Following symptom onset patients are typically transported to the nearest hospital
10 capable of administering IVT, which can be either a Primary Stroke Centre (PSC) or a
11 Comprehensive Stroke Centre (CSC). In parallel with administering the bolus for IVT
12 additional neuroimaging is performed in order to detect large vessel occlusion (LVO). In case
13 of a LVO patients may become eligible for IAT after which transfer to a CSC is arranged, if
14 patients are initially admitted to a PSC.

15 The transfer of patients to a CSC following IVT diagnostic work-up and/or treatment
16 at a PSC is called the drip-and-ship (DS) approach. In addition to the DS approach patients
17 may be transported directly to the CSC bypassing the PSC, which is called the Mothership
18 (MS) approach. Currently there are no formal policies supporting the latter, as it necessitates
19 accurate prehospital triage objectifying LVO with sufficient accuracy. Timely patient arrival
20 and treatment with reperfusion therapies depends on a number of factors such as the
21 geographical distribution and distances between PSCs and CSCs in relation to the location of
22 the patient. Arrangements made by local emergency medical services concerning referral
23 patterns of suspected stroke victims, and the quality and set-up of road networks also play a
24 role, as does potential traffic congestion.

25 In the Netherlands sixteen medical centres that participated in the MR CLEAN trial
26 are currently reimbursed for IAT. However, these hospitals are unevenly distributed leaving
27 certain regions potentially underserved while in some areas there is a surplus of IAT centres.
28 Insight into factors determining the potential optimal and most efficient way to organise acute
29 stroke care is currently lacking but urgently needed to support clinicians and decision-makers.
30 A key question is: what would be the optimal distribution of CSCs within a region, taking into
31 account the effects of additional travel distances, available clinical expertise, treatment
32 volumes and capacity of hospitals? Are there regions under- or overserved with CSCs and
33 what would be the potential consequences of adding/removing CSCs within specific regions?

34 In this study, we aim to quantify pathway logistics, i.e. stroke onset and time delays
35 associated with pre-hospital and intra-hospital care services among patients treated with IAT
36 with or without IVT. From this baseline assessment a simulation model will be built that
37 describes all activities and treatments performed along the acute stroke pathway. A generic
38 model will be developed based on the set-up of IAT delivery in the region of Northern
39 Netherlands, and extended using results of the MR CLEAN registry⁹ and data of 5
40 randomised clinical trials (RCTs) performed in the 'Collaboration for new treatments in acute
41 stroke (CONTRAST)' consortium (www.contrast-consortium.nl). The MR CLEAN registry is
42 an ongoing, prospective, observational study in all centres that perform IAT in the
43 Netherlands. Within CONTRAST 5 large clinical trials will be performed to test novel
44 treatment strategies for stroke. This will be complemented by a pre-clinical program,
45 development of a large biobank and the identification of challenges and solutions for
46 organisational models. Retrospective data from the MR CLEAN registry combined with data
47 from emergency medical services will serve as input for the development of a baseline
48 simulation model for regional IAT delivery. Next, prospective data capturing using results

1 from ongoing trials performed within CONTRAST will be used to further develop the model.
2 Simulation experiments will be performed to assess effectiveness and efficiency of alternative
3 network topologies, i.e. primary and comprehensive stroke services (DS approach) versus a
4 service delivery based on comprehensive and centralised care (MS approach). Model
5 parameters will be extended by assigning unit costs to activities allowing for economic
6 analyses. The latter will involve collection of detailed information on resource use allowing
7 for micro-costing studies and subsequent use in cost-benefit and/or cost-effectiveness
8 analyses.

10 **Aims and hypotheses**

11 *Primary aim:* to develop a simulation model for IAT in the Netherlands and to extend the
12 model to reflect regional differences.

13 *Secondary aims:* to estimate the effectiveness of alternative network topologies on IVT and/or
14 IAT treatment rates, geographical access to CSCs, time to treatment, treatment volumes and
15 patient disability as measured by the modified Rankin Scale (mRS). Also, potential areas for
16 pathway improvements in regional stroke care systems will be identified.

17 *Tertiary aims:* to extend the model with costs estimations of procedures and activities
18 performed along the acute stroke pathway allowing for elaborate economic evaluation. Also,
19 the assessment and potential implementation of new technologies such as the mobile stroke
20 unit is foreseen through modelling.

22 **METHODS**

23 **Study design**

24 This study uses discrete event simulation modelling in which care pathways can be
25 represented 'in silico' by quantifying pathway performance.¹⁰⁻¹² In case of acute stroke
26 treatment, information on time delays sustained by patients and diagnostic steps performed up
27 to treatment with IVT and IAT are collected. In addition, patient demographics (age),
28 exclusion and inclusion criteria and follow-up data up to three months post stroke will be
29 included. Previous research has demonstrated that simulation models for representing the
30 acute stroke pathway can be accurately developed in different settings.¹³⁻¹⁷ Typically,
31 simulation modelling involves a number of consecutive steps including model building,
32 validation and experimentation. Model building starts with the conceptual representation of
33 care pathways in building block such as incidents, time delays, queues, resources and
34 ultimately outcome. Next the model needs to be populated through collection of empirical
35 data reflecting actual pathway performance, for which a combination of real-world datasets
36 are used. For hospital items we will rely on case report forms (CRFs) collected in the RCTs in
37 the CONTRAST consortium involving sixteen hospitals in the Netherlands that provide IAT.
38 In addition, collaboration with regional ambulance services will be set up in order to collect
39 prehospital items such as time of 911 call, time spent on scene, transportation time to the
40 hospital and general referral patterns. Real-world data collected in each step of the pathway
41 will be analysed to distinguish statistical distributions using the statistical software package
42 ExpertFit.¹⁸ Based on the statistical distributions identified hypothetical patients passing
43 through the model will be assigned a certain time delay, and diagnostic accuracy for each step
44 along the pathway. Model outcomes include the proportion of patients treated with IAT, time
45 to treatment and functional outcome after 90 days. These results will then be validated

1
2
3 1 comparing them to observed time delays and outcomes observed in clinical practice.
4 2 Following model validation, experiments will be performed in which scenarios of alternative
5 3 set-ups of the organisational models will be evaluated. Descriptions of the acute stroke
6 4 pathway in both the DS and MS organisational models in Northern Netherlands are presented
7 5 in Figures 1 and 2.
8
9
10 6

11 7 **Study population**

12
13 8 For this study we will use data from acute stroke patients that received IAT with or without
14 9 IVT. A baseline model will be developed using a subset of patient information collected in the
15 10 ongoing cohort study MR CLEAN Registry. Following the initial model patients treated in
16 11 other regions in the Netherlands will be included. In later stages of model development
17 12 alternative treatment modalities may become apparent such as treating patient with IAT up to
18 13 24 hours or including patients that receive prehospital treatment in a mobile stroke unit. The
19 14 acute stroke phase is defined as the time window in which acute reperfusion therapies are
20 15 being used. This can be the case up to a maximum of 24 hours following symptom onset. In
21 16 these cases the parameters underlying the model will be changed accordingly. Modelling the
22 17 hypothetical introduction of a mobile stroke unit will involve changing prehospital stroke
23 18 management. In such a scenario an expedited and optimised process of initial diagnostic
24 19 assessment and triage is assumed.
25
26
27
28 20

29 21 **Public and patient involvement**

30
31 22 Patients and public were involved in the conception of the topics to be addressed in the
32 23 CONTRAST consortium. Study results will be disseminated through newsletters, poster
33 24 presentations, and publications in newspapers, lay journals, and publication in peer-reviewed
34 25 journals.
35
36
37 26

38 27 **Data to be collected**

39
40 28 An overview of all data items collected for the simulation model is presented in a table as
41 29 supplementary material (Table S1. Overview of data collection). Based on this data, time
42 30 intervals reflecting pathway efficiencies will be calculated, such as the time from symptom
43 31 onset to computed tomography (CT)/ computed tomography angiography (CTA) and door-to-
44 32 CT/CTA times for patients arriving at a PSC and after secondary transfer to the CSC, if
45 33 necessary.
46
47
48 34

49 35 *Hospital data*

50
51 36 Within CONTRAST 5 RCTs are performed that serve as input for the proposed simulation
52 37 modelling studies: MR ASAP (NL60258.078.17), MR CLEAN LATE (NL58246.078.17),
53 38 MR CLEAN MED (ISRCTN76741621), MR CLEAN NO IV (ISRCTN80619088). Each
54 39 intervention centre uses a standardised, customised and web-based electronic CRF to
55 40 document all steps in the care process. All data will be entered locally in web-based database
56 41 (OpenClinica). A copy of the CRF documents used in the clinical trials can be found online
57 42 (www.contrast-consortium.nl). All studies aim to collect a large set of items containing,
58 43 among others, a description of the workflow including time of symptom onset or last seen
59
60

1 well, time of arrival of the first hospital and whether the patient was transferred from another
2 hospital. Within the hospital, time to CT scan and advanced imaging (computed tomography
3 angiography/ magnetic resonance angiography/digital subtraction angiography/perfusion
4 imaging) are collected according to local procedures. Also start of IVT (bolus infusion),
5 patient arrival in the angiosuite, groin puncture, device attempts, recanalisation and sheath
6 withdrawal/end of procedure are collected. In addition anesthetic team presence and
7 management procedures are recorded.

8 9 *Prehospital data*

10 For the collection of prehospital data collaboration with regional ambulance services is being
11 set-up. Items will include time delays, diagnostics and geographic information on referral
12 patterns. Time delays include the time of 911 call, arrival at the location of the patient,
13 departure at the location of the patient and arrival at the hospital. Diagnostic items include
14 mode of referral (general practitioner, 911 or other), initial working diagnosis set by 911
15 dispatch and ambulance personnel and the level of urgent transportation (i.e. blue lights or
16 other). Geographical information includes the postal codes of the location of the patient,
17 departure location of the ambulance vehicle and location of the PSC and/or CSC.

18 19 *Baseline data*

20 Prior to the CONTRAST study, all hospitals contributed to the MR CLEAN Registry, an
21 online and ongoing database to monitor implementation and safety of IAT in the
22 Netherlands.⁹ For CONTRAST the variables are similar to those collected in the MR CLEAN
23 Registry. In addition, prehospital information available at regional ambulance services will be
24 collected.

25 The baseline discrete event simulation model will be developed using data from 296
26 patients that received IAT at the University Medical Centre Groningen between July 2014 and
27 November 2017. For these patients intrahospital time delays and diagnostic steps were already
28 collected as part of the ongoing MR CLEAN Registry and subsequently used for model
29 development and validation. In addition, prehospital items as described above were collected
30 in collaboration with regional ambulance services.

31 32 **Outcome measures**

33 Outcomes will be estimated by the simulation model using parameter distributions as
34 observed in clinical practice using real-world data.

35 *Primary outcomes* include IAT treatment rates and clinical outcome according to the modified
36 Rankin Scale (mRS).

37 *Secondary outcomes* include process times such as symptom onset to hospital arrival, door to
38 needle and groin puncture, arrival angiosuite, recanalization, onset-to-treatment time of IVT
39 and/or IAT and interhospital transportation times for those patients that were transferred to a
40 CSC after initial diagnosis and/or treatment with IVT at a PSC. In addition, the time interval
41 of referral from the PSC to CSC is included.

42 *Tertiary outcomes* include treatment volume, direct costs, indirect costs and societal costs.
43 This will include fixed and variable costs of providing services related to IAT delivery.

1 **Ethics and dissemination**

2 Both the MR CLEAN and CONTRAST databases include patients for which informed
3 consent had been obtained, which was extended for use in our simulation modeling study. All
4 data used for model building has been completely anonymized, performed by local
5 researchers under auspices of the principal investigators for the MR CLEAN Registry and
6 CONTRAST studies. Accordingly, no additional approval from our local ethics committee is
7 required, as this represents a simulation study using an anonymized dataset.

8 In order to link data collected of patients treated with IAT after study enrollment in the
9 hospital to corresponding data collected by ambulance services, identifiable information from
10 patients will be used under a strict protocol compliant with the Dutch Personal Data
11 Protection Act. This protocol for using prehospital ambulance data meets the criteria for a
12 waiver of consent from the University Medical Centre Groningen Institutional Review Board,
13 for which formal approval was already obtained. Following successful linking of pre-and
14 in-hospital data, note however, that also these data were anonymized. Prior to the exchange of
15 information, a data transfer and processing agreement was agreed upon and signed by each
16 provider of regional ambulance services.

17 Study results will be published in peer-reviewed journals and (inter)national conference
18 presentations. Centres that have participated in the study will have access to their own data
19 and results.

21 **Study sites**

22 Sixteen hospitals providing IAT will participate. In addition, regional ambulance services in
23 the catchment area of intervention centres will be asked to participate. The overview of
24 intervention centres, their catchment area and regional ambulance services active in the region
25 are provided as supplementary material (Figure S1. Overview of IAT centres and ambulance
26 services).

28 **Statistical analyses**

29 Descriptive statistics will be used to characterise the population and regional differences.
30 Mann-Whitney U and Fisher's exact tests are used to estimate the differences for continuous
31 and categorical variables. Model and parameter uncertainty will be tested using sensitivity
32 analyses.

34 *Approach to missing data*

35 Multiple imputation techniques will be used to handle missing data. The impact of missing
36 data will be analysed by performing sensitivity analyses. Once missing data or errors are
37 identified, all corrections made will be documented. All data will be documented and
38 displayed in an appropriate flow diagram.

40 *Model validation*

41 Internal validation will be performed by comparing model performance with observed
42 performance of the stroke system to ascertain whether the model represented the real system

1 accurately. External validation of the baseline model will be performed by using the pathway
2 performance of other PSCs and CSCs participating in the CONTRAST consortium. As such,
3 the model developed for one region will be extended to other parts of the Netherlands by
4 changing the distributions underlying the simulation model. This means that the model is re-
5 populated by real-world data originating from different regions, including both intrahospital
6 and prehospital data. As we will adopt one uniform method for data collected in both the pre-
7 and intrahospital pathway, similar procedures for model building, validation and
8 experimentation can be followed.

10 **Study organisation**

11 The CONTRAST consortium is a nationwide collaboration of clinical and translational
12 scientists from all academic and large clinical centres who want to act together to improve the
13 treatment of acute stroke in the Netherlands. Five large acute stroke trials to test novel
14 treatment strategies will be performed including: prehospital augmentation of collateral blood
15 flow and blood pressure management (MR ASAP), antithrombotics to prevent microvascular
16 occlusion after IAT (MR CLEAN MED), immediate IAT without preceding thrombolysis
17 (MR CLEAN NO IV), IAT in the 6 to 24 hour time window (MR CLEAN LATE) and
18 minimally invasive endoscopy guided surgery for intracerebral hemorrhage (Dutch ICH trial).
19 Discrete event simulation modelling is applied with data from these trials to optimise acute
20 stroke care delivery.

22 **DISCUSSION**

23 This simulation modelling study will evaluate the set-up of acute stroke services for patients
24 receiving IAT in a specific geographical setting, i.e., the Netherlands. However, the model
25 foreseen may also serve as a planning and evaluation tool for other regions and countries.
26 Already from an early phase onwards the potential consequences of the clinical trials
27 performed in CONTRAST on the organisation of acute stroke care will be assessed. Benefits
28 of innovations foreseen in prehospital as well as hospital based diagnosis and treatment will
29 be estimated on a regional and national scale. Likewise, the optimal organisation ensuing
30 from these re-organising care processes may be identified and taken into account given
31 available resources and capacity. Another important aspect that will be studied is how re-
32 distribution of PSCs and CSCs within certain regions will affect time to treatment for both
33 IVT and IAT.¹⁹ Experiments from simulation models will help to elucidate factors
34 determining optimal stroke pathway set-up and identify potential targets for further
35 optimisation of pathway performance. Simulation modelling also allows for making exact
36 estimations on effects on patients health and costs when adding or removing IAT centres in
37 specific regions, thereby supporting clinicians and policy makers in decision making.¹⁵

38 Our simulation modelling approach has several strengths. First, the prospective design
39 and uniform methods for data collection both in the pre- and intrahospital phase will ensure a
40 high quality of data capture. The use of real-world data will support the external validation of
41 results obtained and is a unique feature of the proposed modelling study. Also in terms of
42 efficiency simulation modelling is an attractive option, as it utilizes already collected
43 information in clinical trials and by ambulance services. Second, the model will have a
44 comprehensive scope, contrary to current improvement approaches characterised by mono-
45 dimensional interventions.²⁰⁻²² Implementation problems such as how many CSCs would a
46 region need or where they should ideally be located require a multi-faceted solution, and

1
2
3 1 could therefore benefit from a modelling approach. Data used for model input will be
4 2 collected in various regions of the Netherlands reflecting differences in access to PSCs and
5 3 CSCs, road networks and potential traffic congestion. Third, the model builds on a previously
6 4 developed simulation model for IVT treatment in Northern Netherlands.¹⁰ As such we have
7 5 demonstrated that model building and validation is feasible. Finally, the model can be
8 6 extended to include unit costs for elaborate economic analyses. The comprehensive character
9 7 of the modelling approach also allows considering potential interaction effects between
10 8 variables, and has a quadruple dimensional approach in terms of measuring outcomes, as it
11 9 can capture effects on clinical outcomes, time to treatment, referral patterns and costs of
12 10 processes associated with IVT and IAT delivery.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11 Serving as a precursor for clinical validation, results obtained from modelling studies
12 should always be interpreted with care as these results do not represent actual patients.
13 However, from an economics and business approach each treatment can be represented as the
14 sum of time delays and diagnostics performed along the care pathway, and as such can be
15 quantified and in turn represented ‘*in silico*’ by computer models. One of the main questions
16 is whether there is benefit in bypassing the nearest PSC to transport the patient directly to a
17 CSC. At the moment there is no consensus which prehospital scale to use in order to quantify
18 stroke severity, and no agreed upon triage instrument exists to guide transfer of patients to
19 specific hospitals. Typically, in case of a positive trial results in CONTRAST this will have a
20 direct impact on the organisational model for IAT delivery, either by suggesting to bypass
21 PSCs (MR CLEAN NO IV), by extending the time window for reperfusion therapies (MR
22 CLEAN LATE) or to change prehospital stroke management (MR ASAP). As a consequence
23 alternative set-up of services is foreseen, in which accurate estimations on effectiveness, time
24 to treatment and cost-effectiveness are required to support decision-making.

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26 In summary, the proposed modelling study will investigate current organisational models for
27 IAT delivery in the Netherlands. Based on input from real-world clinical studies performed in
28 the CONTRAST consortium insight into current treatment delays and workflow performance
29 of IAT centres will be obtained. Next, simulation modelling studies will support design of
30 optimal distribution of IAT centres, in order to improve patient outcomes and increase the
31 proportion of patients eligible for IAT.

33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33 **Acknowledgements** We acknowledge the support of the Netherlands Cardiovascular
34 Research Initiative which is supported by the Dutch Heart Foundation (CVON2015-01:
35 CONTRAST), the support of the Brain Foundation Netherlands (HA2015.01.06), and the
36 support of Health~Holland, Top Sector Life Sciences & Health (LSHM17016) and of
37 Medtronic.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39 **Contributors** ML, WM, DJZ, MU and EB designed the study with MU and EB as principal
40 investigators. ML, MU and EB applied for, received and organised study funding. ML drafted
41 the manuscript, WM, DJZ, MU and EB critically revised the manuscript for intellectual
42 content and approved the final version of the manuscript for publication.

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44 **Funding** The CONTRAST consortium is supported by Netherlands Cardiovascular Research
45 Initiative, an initiative of the Dutch Heart Foundation, by the Brain Foundation Netherlands

1
2
3 1 and powered by Health~Holland, Top Sector Life Sciences and receives unrestricted funding
4 2 from Medtronic.
5

6 3

7
8 4 **Competing interest statement** The authors declare that there is no conflict of interest.
9 5

10
11 6 **Figure 1.** Description of the drip-and-ship model.

12
13 7 **Figure 2.** Description of the mothership model.
14 8

15 8

16 9

17 10

18 10

19 11

20 11

21 12

22 12

23 13

24 13

25 **References**

- 26 14 1 . Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological
27 15 Disorders and Stroke rt-PA Stroke Study Group. *N Engl J Med* 1995;333:1581-7
28 16 doi:10.1056/NEJM199512143332401.
- 29
30 17 2 Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute
31 18 ischemic stroke. *N Engl J Med* 2015;372:11-20 doi:10.1056/NEJMoa1411587 [doi].
- 32
33 19 3 Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
34 20 perfusion-imaging selection. *N Engl J Med* 2015;372:1009-18 doi:10.1056/NEJMoa1414792 [doi].
- 35
36 21 4 Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment
37 22 of ischemic stroke. *N Engl J Med* 2015;372:1019-30 doi:10.1056/NEJMoa1414905 [doi].
- 38
39 23 5 Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in
40 24 ischemic stroke. *N Engl J Med* 2015;372:2296-306 doi:10.1056/NEJMoa1503780 [doi].
- 41
42 25 6 Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA
43 26 alone in stroke. *N Engl J Med* 2015;372:2285-95 doi:10.1056/NEJMoa1415061 [doi].
- 44
45 27 7 Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a
46 28 Mismatch between Deficit and Infarct. *N Engl J Med* 2018;378:11-21 doi:10.1056/NEJMoa1706442
47 29 [doi].
- 48
49 30 8 Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and
50 31 Outcomes From Ischemic Stroke: A Meta-analysis. *JAMA* 2016;316:1279-88
51 32 doi:10.1001/jama.2016.13647 [doi].
- 52
53 33 9 Jansen IGH, Mulder MJHL, Goldhoorn RB, et al. Endovascular treatment for acute ischaemic stroke
54 34 in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). *BMJ*
55 35 2018;360:k949 doi:10.1136/bmj.k949 [doi].
56
57
58
59
60

- 10 Lahr MM, van der Zee DJ, Vroomen PC, et al. Thrombolysis in acute ischemic stroke: a simulation study to improve pre- and in-hospital delays in community hospitals. *PLoS One* 2013;8:e79049 doi:10.1371/journal.pone.0079049 [doi].
- 11 Ramwadhoebe S, Van Merode GG, Boere-Boonekamp MM, et al. Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the Netherlands. *BMC Health Serv Res* 2010;10:75 doi:10.1186/1472-6963-10-75.
- 12 Heeg BM, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia. *Pharmacoeconomics* 2008;26:633-48 doi:2682 [pii].
- 13 Holodinsky JK, Williamson TS, Demchuk AM, et al. Modeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion. *JAMA Neurol* 2018;75:1477-86 doi:10.1001/jamaneurol.2018.2424 [doi].
- 14 Phan TG, Beare R, Chen J, et al. Googling Service Boundaries for Endovascular Clot Retrieval Hub Hospitals in a Metropolitan Setting: Proof-of-Concept Study. *Stroke* 2017;48:1353-61 doi:10.1161/STROKEAHA.116.015323 [doi].
- 15 Lahr MM, van der Zee DJ, Luijckx GJ, et al. Centralising and optimising decentralised stroke care systems: a simulation study on short-term costs and effects. *BMC Med Res Methodol* 2017;17:5,016-0275-3 doi:10.1186/s12874-016-0275-3 [doi].
- 16 Monks T, Pitt M, Stein K, et al. Maximizing the Population Benefit From Thrombolysis in Acute Ischemic Stroke: A Modeling Study of In-Hospital Delays. *Stroke* 2012;43(10):2706-11 doi:10.1161/STROKEAHA.112.663187.
- 17 Churilov L, Fridriksdottir A, Keshtkaran M, et al. Decision support in pre-hospital stroke care operations: a case of simulation to improve eligibility of acute stroke patients for thrombolysis treatment. *Computer & Operations Research*, Available online 14 July 2012.
- 18 Law AM. ExpertFit Version 8 User's Guide. Tuscon, Arizona: Averill M. Law & Associates 2011.
- 19 Allen M, Pearn K, James M, et al. Maximising access to thrombectomy services for stroke in England: A modelling study. *Eur Stroke J* 2019;4:39-49 doi:10.1177/2396987318785421 [doi].
- 20 Jeon SB, Ryoo SM, Lee DH, et al. Multidisciplinary Approach to Decrease In-Hospital Delay for Stroke Thrombolysis. *J Stroke* 2017;19:196-204 doi:10.5853/jos.2016.01802 [doi].
- 21 Psychogios MN, Behme D, Schregel K, et al. One-Stop Management of Acute Stroke Patients: Minimizing Door-to-Reperfusion Times. *Stroke* 2017;48:3152-5 doi:10.1161/STROKEAHA.117.018077 [doi].
- 22 Schregel K, Behme D, Tsogkas I, et al. Effects of Workflow Optimization in Endovascularly Treated Stroke Patients - A Pre-Post Effectiveness Study. *PLoS One* 2016;11:e0169192 doi:10.1371/journal.pone.0169192 [doi].

Figure legends

Figure 1. Description of the drip-and-ship model.

Figure 2. Description of the Mothership model.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

For peer review only




Figure 1

356x206mm (96 x 96 DPI)




Figure 2

356x207mm (96 x 96 DPI)

Supplementary files

Table S1. Overview of data collection [Table S1.docx] – supplementary material for “Rationale and design of a simulation modelling approach for intra-arterial thrombectomy in the Netherlands” by Lahr M.M. et al.

Table 1. Overview of data collection.

Item	Description	Source
<u>Prehospital items</u>		
Symptom onset	Exact time of stroke onset, last seen well or symptoms noticed	CRF
Mode of referral	Initial call for help directed at either the GP, 911 emergency services or via self-transport	Ambulance database
Time first 911 call	Moment of first 911 call as documented at the control centre of the regional ambulance service	Ambulance database
Time second 911 call†	Moment of second 911 call as documented at the control centre of the regional ambulance service	Ambulance database
Time departure ambulance patient	Moment of ambulance departure in the direction of the patient	Ambulance database
Time departure ambulance hospital	Moment of ambulance departure in the direction of the PSC for transfer to the CSC	Ambulance database
Time ambulance arrival patient	Moment of ambulance arrival at the location of the patient	Ambulance database
Time ambulance arrival first hospital	Moment of ambulance arrival at the first hospital	Ambulance database
Time ambulance arrival second hospital†	Moment of ambulance arrival at the second hospital	Ambulance database
Time ambulance arrival PSC†	Moment of ambulance arrival at the PSC to transfer a patient to the CSC	Ambulance database
Procedures at location patient	All procedures performance by ambulance personnel at the location of the patient	Ambulance database
Postal code patient	Exact geographic location of the patient	Ambulance database
Postal code hospital	Exact geographical location of the destination hospital	Ambulance database
<u>Intrahospital items</u>		
Time of arrival ER first hospital	Moment of patient entry into the hospital electronic system	CRF
Time of arrival ER intervention hospital	Moment of patient entry into the hospital electronic system	CRF
Time of CT scan first hospital	Moment of CT scan performance in the first hospital	CRF
Time of CT scan second hospital	Moment of CT scan performance in the second hospital	CRF
Time of CTA scan first hospital	Moment of CTA scan performance in the first hospital	CRF
Time of CTA scan second hospital	Moment of CTA scan performance in the second hospital	CRF

Time of IV alteplase bolus (if given)	Moment of intravenous thrombolysis	CRF
Time of angiosuite arrival	Moment of patient arrival at the angiosuite	CRF
Time groin puncture	Moment of groin puncture	CRF
Time device attempt	Moment of device attempt	CRF
Time recanalisation	Time of recanalisation	CRF
Time of end procedure	Moment of sheath withdrawal/end of procedure	CRF

CRF indicates case report form; PSC, primary stroke centre; CSC, comprehensive stroke centre; CT, computed tomography; CTA, computed tomography angiogram.

†In case of intravenous thrombolysis at the primary stroke centre followed by intra-arterial thrombectomy at the comprehensive stroke centre (drip-and-ship approach).

Figure S1. Overview of IAT centres and ambulance services [Supplementary figure S1.tiff] - supplementary material for “Rationale and design of a simulation modelling approach for intra-arterial thrombectomy in the Netherlands” by Lahr M.M. et al.

